View More
Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021
Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021
Lenacapavir, in combination with an optimized background regimen, showed favorable efficacy and safety in patients with MDR HIV-1 infection from IAS 2021, as reported by Clinical Care Options (CCO).
Dr Adeeba Kamarulzaman previews 11th IAS Conference on HIV Science, with official coverage and analysis from Clinical Care Options (CCO)
Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc
Released: July 19, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.